The DOI matches its Crossref record; 219 of the 219 references it cites were found in a registry or an index.
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Open accessAbstract
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders. Here, the elucidation of key pathogenic factors such as IL-17A/IL-23 on the one hand and IL-4/IL-13 on the other hand profoundly changed our therapeutic practice. The knowledge on intracellular pathways and governing factors is shifting our attention to new druggable molecules. Multiple cytokine receptors signal through Janus kinases (JAKs) and associated signal transducer and activators of transcription (STATs). Inhibition of JAKs can simultaneously block the function of multiple cytokines. Therefore, JAK inhibitors (JAKi) are emerging as a new class of drugs, which in dermatology can either be used systemically as oral drugs or locally in topical formulations. Inhibition of JAKs has been shown to be effective in various skin disorders. The first oral JAKi have been recently approved for the treatment of rheumatoid arthritis and psoriatic arthritis. Currently, multiple inhibitors of the JAK/STAT pathway are being investigated for skin diseases like alopecia areata, atopic dermatitis, dermatomyositis, graft-versus-host-disease, hidradenitis suppurativa, lichen planus, lupus erythematosus, psoriasis, and vitiligo. Here, we aim to discuss the immunological basis and current stage of development of JAKi in dermatology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–219 of 219
Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib
Sarny, S., Hucke, M., & El‐Shabrawi, Y. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.3789 · Cited by 40
Managing side effects of JAK inhibitors for myelofibrosis in clinical practice
Saeed, I., McLornan, D. P., & Harrison, C. N. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1337507 · Cited by 36
Weinhold, K. J., Bukowski, J. F., Brennan, T. V., Noveck, R. J., Staats, J. S., Lin, L., Stempora, L., Hammond, C., Wouters, A., Mojcik, C. F., et al. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.03.002 · Cited by 35
Almanzar, G., Kienle, F., Schmalzing, M., Maas, A., Tony, H., & Prelog, M. (2019) · Rheumatology · doi:10.1093/rheumatology/kez175 · Cited by 35
Fujii, Y., & Sengoku, T. (2013) · Pharmacology · doi:10.1159/000347184 · Cited by 30
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations
Hammarén, H. M., Virtanen, A. T., Abraham, B. G., Peussa, H., Hubbard, S. R., & Silvennoinen, O. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.07.022 · Cited by 30
Kimball, A. B., Tzellos, T., Calimlim, B., Teixeira, H. D., Geng, Z., & Okun, M. S. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-3012 · Cited by 30
Ansprechen einer Dermatomyositis mit Lungenbeteiligung auf eine Januskinase-Inhibitor-Therapie
Hörnig, J., Weinhage, T., Schmidt, L., Buerke, B., Schneider, U., Pavenstädt, H. J., Becker, H., & Gabriëls, G. (2018) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-018-0565-8 · Cited by 30
Genome-Wide MicroRNA Analysis Implicates miR-30b/d in the Etiology of Alopecia Areata
Tafazzoli, A., Forstner, A. J., Broadley, D., Hofmann, A., Redler, S., Petukhova, L., Giehl, K. A., Kruse, R., Blaumeiser, B., Böhm, M., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.046 · Cited by 28
Tavakolpour, S. (2018) · Dermatologic Therapy · doi:10.1111/dth.12696 · Cited by 28
Relationship of structure to function of muscle phosphorylase.
Fischer, E. H., & Krebs, E. G. (1967) · PubMed · Cited by 27
Novikova, D. S., Udachkina, H. V., Markelova, E. I., Геннадьевна, К. И., Misiyuk, A. S., Demidova, N. V., & Попкова, Т. В. (2019) · Rheumatology International · doi:10.1007/s00296-019-04303-x · Cited by 23
Davies, R., Hammenfors, D., Bergum, B., Vogelsang, P., Gavasso, S., Brun, J. G., Jonsson, R., & Appel, S. (2018) · European Journal of Immunology · doi:10.1002/eji.201747213 · Cited by 21
Morris, G. M., Nahmias, Z. P., & Kim, B. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.12.016 · Cited by 21
Bedeutung des follikulären Penetrationswegs für den Wirkstofftransport mittels Nanocarriern
Lademann, J. M., Richter, H., Schanzer, S., Meinke, M. C., Darvin, M. E., Schleusener, J., Carrer, V., Breuckmann, P., & Patzelt, A. (2019) · Der Hautarzt · doi:10.1007/s00105-018-4343-y · Cited by 21
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors
Dai, J., Yang, L., & Addison, G. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666190617152011 · Cited by 19
Hadj-Slimane, R., Chelbi‐Alix, M. K., Tovey, M. G., & Bobé, P. (2004) · Journal of Interferon & Cytokine Research · doi:10.1089/1079990042722882 · Cited by 17
Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib
Haugh, I. M., Watson, I., & Menter, A. (2018) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2018.1480246 · Cited by 14
Yiu, G., Rasmussen, T. K., Ajami, B., Haddon, D. J., Chu, A. D., Tangsombatvisit, S., Haynes, W. A., Diep, V. K., Steinman, L., Faix, J. D., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39535 · Cited by 12
Cited by
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Self-citationEuropean guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Wollenberg, A., Kinberger, M., Arents, B., Aszodi, N., Avila Valle, G., Barbarot, S., Bieber, T., Brough, H. A., Calzavara Pinton, P., Christen‐Zäch, S., et al. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18345 · Cited by 426
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management
Zhou, C., Li, X., Wang, C., & Zhang, J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08883-0 · Cited by 393
Nash, P., Kerschbaumer, A., Dörner, T., Dougados, M., Fleischmann, R. M., Geissler, K., McInnes, I., Pope, J. E., van der Heijde, D., Stoffer-Marx, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218398 · Cited by 299
New Treatment Addressing the Pathogenesis of Psoriasis
Tokuyama, M., & Mabuchi, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207488 · Cited by 291
Metadata
- Authors
- Solimani, F., Meier, K., & Ghoreschi, K.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-12-03
- Volume
- 10
- Pages
- 2847-2847
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2990076552
- Cited by
- 308
- References
- 219
- FWCI
- 11.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.